ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 1338 • ACR Convergence 2020

    Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study

    Atlas Mashayekhi Sardoo1, Daniel Sobral2, Lucia Domingues3, Santiago Rodrigues-Manica4, Rita Pinheiro Torres4, Agna Neto5, Ana Filipa Fernandes6, Patricia Alves7, Julia Costa6, Ana Rita Grosso2, Celso Cunha8, Jaime Branco9 and Fernando M Pimentel-Santos4, 13. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 2Faculty of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal, 3NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal, 4CHLO, Hospital Egas Moniz, Lisbon, Portugal, 51. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, 6ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal, 7IBET - Institute of Experimental Biology and Technology, Oeiras, Portugal, 8Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Lisbon, Portugal, 92. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal

    Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…
  • Abstract Number: 1849 • ACR Convergence 2020

    Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study

    Jesus Miguens Blanco1, Uma Selvarajah1, Zhigang Lui1, Benjamin Mullish1, James Alexander1, Julie McDonald2, Sonya Abraham1 and Julian Marchesi1, 1Imperial College London, London, United Kingdom, 2Imperial College London, London

    Background/Purpose: Perturbations of the gut microbiota have been associated with Psoriatic Arthritis (PsA), a chronic inflammatory disease. We aim to test the microbiome-metabolic interface of…
  • Abstract Number: 1884 • ACR Convergence 2020

    Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic

    Jean Liew1, Maria Castillo2, Ethan Zaccagnino2, Patricia Katz3, Nigil Haroon4 and Lianne Gensler5, 1University of Washington, Seattle, WA, 2UCSF, San Francisco, CA, 3University of California, San Francisco, Novato, CA, 4University of Toronto, Toronto, ON, Canada, 5University of California San Francisco, San Francisco, CA

    Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…
  • Abstract Number: 2024 • ACR Convergence 2020

    Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial

    Walter Maksymowych1, Mikkel Østergaard2, Robert Landewé3, William Barchuk4, Ke Liu4, Chantal Tasset5, Leen Gilles5, Thijs Hendrikx6, Robin Besuyen6 and Xenofon Baraliakos7, 1University of Alberta, Edmonton, AB, Canada, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Galapagos BV, Leiden, Netherlands, 7Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
  • Abstract Number: 0369 • ACR Convergence 2020

    Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs

    Atul Deodhar1, Xenofon Baraliakos2, Iain McInnes3, Kurt de Vlam4, Louis Bessette5, Anna Maniccia6, Ralph Lippe7, Christopher Saffore6, Tianming Gao6, In-Ho Song6 and Andrew Östör8, 1Oregon Health & Science University, Portland, OR, 2Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, 3Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…
  • Abstract Number: 1303 • ACR Convergence 2020

    Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort

    Ulrich Weber1, Raj Carmona2, James Yeung3, Jon Chan4, Liam Martin5, Ariel Masetto6, Stephanie Keeling7, Olga Ziouzina5, Sherry Rohekar8, Rana Dadashova9, Joel Paschke9, Amanda Carapellucci9, Robert G Lambert10, Walter Maksymowych7 and Sibel Aydin11, 1University of South Denmark, Odense, Denmark, 2St. Joseph's Healthcare, Hamilton, ON, Canada, 3James Yeung Rheumatology, Vancouver, BC, Canada, 4Artus Health Clinic, Vancouver, BC, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Sherbrooke, Sherbrooke, QC, Canada, 7University of Alberta, Edmonton, AB, Canada, 8Lawson Health Research Institute, London, ON, Canada, 9CARE Arthritis, Edmonton, AB, Canada, 10University of Alberta and CARE Arthritis, Edmonton, AB, Canada, 11University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada

    Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
  • Abstract Number: 1346 • ACR Convergence 2020

    Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis

    Runsheng Wang1, Abhijit Dasgupta2 and Michael Ward3, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2NIAMS, Bethesda, 3National Institutes of Health, Bethesda, MD

    Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous.  In clinical practice, both patients and…
  • Abstract Number: 1858 • ACR Convergence 2020

    Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden

    Kristina Lejon1, Urban Hellman2, Lan Do2, Anjani Kumar2 and Helena Forsblad-d'Elia3, 1Department of Clinical microbiology, Infection and Immunology, Umeå University, Umeå, Sweden, 2Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden, 3Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Vasterbottens Lan, Sweden

    Background/Purpose: Increased levels of TH17 and TH22 as well as TC17 and TC22 cells have previously been associated with ankylosing spondylitis (AS). The correlation between…
  • Abstract Number: 1885 • ACR Convergence 2020

    Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial

    Emilce Schneeberger1, Gustavo Citera2, Dario Ponce de Leon3, Annette Szumski4, Kenneth Kwok5, Mariel Cutri6 and Maxime Dougados7, 1Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3PFIZER, LIMA, Peru, 4Syneos Health, Princeton, 5Pfizer, New York, NY, 6Pfizer, Buenos Aires, Argentina, 7Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France

    Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…
  • Abstract Number: 0371 • ACR Convergence 2020

    Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States

    Theresa Hunter1, Michael Grabner2, Keith Isenberg3, Mingyang Shan4, Chia-Chen Teng2, Jeffrey Lisse4 and Jeffrey R Curtis5, 1Eli Lilly and Company, Indianapolis, 2Healthcore, Inc, Wilmington, DE, 3Anthem, Inc, Indianapolis, IN, 4Eli Lilly and Company, Indianapolis, IN, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year from biologic initiation among ankylosing spondylitis (AS)…
  • Abstract Number: 1305 • ACR Convergence 2020

    Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS

    Sjef van der Linden1, Peter Villiger2, Zhixiu Li3, Matthew Brown4, Heinz Baumberger5, Hermine Zandwijk6 and Muhammad Khan7, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, 2Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 3Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, 4Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, 5Retired, Flims, Tajikistan, 6Retired, Mortroux, Belgium, 7Case Western Reserve University, Cleveland OH, Westlake, OH

    Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…
  • Abstract Number: 1354 • ACR Convergence 2020

    The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis

    Mark Siderius1, Freke Wink1, Anneke Spoorenberg1 and Suzanne Arends1, 1University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
  • Abstract Number: 1862 • ACR Convergence 2020

    Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years

    Muhammad Khan1, Sjef van der Linden2, Peter Villiger3, Zhixiu Li4, Mohammad Khan5, Heinz Baumberger6, Hermine Zandwijk7 and Matthew Brown8, 1Case Western Reserve University, Cleveland OH, Westlake, OH, 2Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, 3Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 4Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, 5Kent State University, Kent, OH, 6Retired, Flims, Tajikistan, 7Retired, Mortroux, Belgium, 8Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom

    Background/Purpose: To investigate the recurrence rate (RR) of ankylosing spondylitis (AS) over a lifespan, probands with clinically diagnosed AS and their first-degree relatives (FDRs) were…
  • Abstract Number: 1889 • ACR Convergence 2020

    Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients

    Yvette Farran1, Alexis Ogdie2, John Reveille3 and Mark Hwang4, 1McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, 2University of Pennsylvania, Philadelphia, PA, 3Department of Internal Medicine, University of Texas, Houston, TX, 4McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…
  • Abstract Number: 0373 • ACR Convergence 2020

    Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study

    Emmanouil Rampakakis1, Yoram Shir2, John Sampalis1, Martin Cohen2, Michael Starr2, Winfried Häuser3 and Mary-Ann Fitzcharles2, 1JSS Medical Research, St-Laurent, QC, Canada, 2McGill university, montreal, Canada, 3Technische Universität München, Munich, Germany

    Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology